The Ac-225 Bottleneck: Who Actually Controls the Alpha Emitter Supply Chain?

Every targeted alpha therapy programme in the world runs through the same bottleneck. Not the antibody. Not the linker. Not the regulatory pathway. The isotope.

Actinium-225 is the alpha emitter that most of the current wave of targeted alpha therapy programmes are built around. It is the fuel. And the global supply of Ac-225 is so constrained, so concentrated in so few hands, that it has become the single most important variable in determining which radiopharma programmes will advance, which will stall, and which will never reach the clinic.

This is not a theoretical concern. It is an operating reality that every executive in the radiopharmaceutical sector is navigating right now.

The Supply Landscape Today

The global supply of Ac-225 comes from a small number of sources, and the vast majority of current production relies on a method that was never designed for pharmaceutical-scale output.

Most Ac-225 available today is extracted from the decay of thorium-229, which itself is a byproduct of legacy Cold War-era uranium-233 stockpiles. The US Department of Energy's Oak Ridge National Laboratory has historically been the dominant source, alongside smaller contributions from facilities in Russia, Germany, and Canada. Total global production from these sources has been measured in fractions of a curie per year. To put that in context, a single patient course of a targeted alpha therapy can require a meaningful fraction of the entire world's monthly supply.

The arithmetic is brutal. If even a handful of Ac-225-based programmes reach late-stage clinical trials simultaneously, the current supply infrastructure cannot support them all. If one reaches commercialisation, the supply gap becomes a crisis.

Who Is Trying to Solve It

Several organisations are pursuing alternative production methods to break the thorium-229 dependency. The approaches fall into three broad categories.

Accelerator-based production. Companies and institutions including TRIUMF in Canada, Niowave in the US, and several others are developing cyclotron and linear accelerator-based methods to produce Ac-225 from radium-226 targets. This approach has the theoretical advantage of being scalable without relying on legacy nuclear stockpiles. The challenge is yield. Accelerator-produced Ac-225 must achieve pharmaceutical-grade purity and sufficient activity to be commercially viable, and not all irradiation methods produce isotope of consistent quality.

Reactor-based production. Some organisations are exploring neutron irradiation pathways in nuclear reactors. This approach could theoretically produce larger quantities, but it introduces different challenges around target processing, waste handling, and regulatory licensing.

Decay-chain harvesting from thorium-229. Efforts to expand the existing thorium-229 based supply include extracting more material from DOE stockpiles and potentially producing thorium-229 from uranium-233. This is constrained by the finite nature of the stockpile and the regulatory complexity of working with weapons-programme-derived nuclear materials.

Each of these approaches is at a different stage of maturity. None of them is producing Ac-225 at the scale required to support multiple commercial programmes today.

The Strategic Implications

The isotope supply question is not just a chemistry problem. It is a corporate strategy problem, an investment thesis problem, and a talent problem.

For radiopharma developers: your clinical programme timeline is ultimately determined by whether you can secure enough isotope to run your trial. If you are in Phase 2 and your isotope supply agreement expires before Phase 3, you may not be able to dose patients. This is happening now. The companies that will succeed are the ones locking in long-term supply agreements, investing in redundant sourcing, or vertically integrating isotope production. The rest are hoping the supply problem gets solved by someone else before their clinical timelines force the issue.

For investors: the isotope supply concentration creates a specific type of risk that most biotech investment models do not adequately capture. A programme can have perfect biology, clean clinical data, and a favourable regulatory pathway, and still fail because it cannot source enough Ac-225 to manufacture at commercial scale. Due diligence on radiopharma investments must include a hard-eyed assessment of isotope supply security, not just molecule potential.

For CDMOs: the contract manufacturers who can handle Ac-225, who have the hot-cell infrastructure, the radiation safety licensing, the trained personnel, and the quality systems to label and fill alpha-emitting radiopharmaceuticals, will command extraordinary pricing power. There are very few of them. Building more takes years, not months, because the talent required to operate these facilities does not exist at scale.

The Talent Dimension

Every part of this supply chain requires people who are extraordinarily difficult to find.

Nuclear chemists who can process actinium targets. Health physicists who can design and certify production facilities. Radiochemists who can develop and validate labelling processes. Quality leaders who understand both FDA pharmaceutical requirements and NRC radiation safety requirements simultaneously. Site heads who can run facilities where the product is lethal if mishandled.

We covered the talent scarcity across the radiopharmaceutical sector in depth in our 2026 industry report, The State of Radiopharmaceuticals, which maps the operating reality across isotope supply, manufacturing infrastructure, regulatory divergence, and workforce constraints globally. You can access it in our premium reports section.

If You Are Hiring in Radiopharma

The Ac-225 supply chain is creating a new category of leadership roles that did not exist five years ago. Heads of isotope supply chain. Directors of nuclear operations. VP-level manufacturing leaders who can bridge the gap between nuclear science and pharmaceutical GMP. If you are building a team around targeted alpha therapy, we would welcome a confidential conversation.

Byron Fitzgerald is the Founder of ProGen Search, a retained executive search and market intelligence firm serving life sciences, radiopharma, CDMO, ADC, and cell and gene therapy sectors.